Navigation Links
NPS Pharmaceuticals Commences Tender Offer for 3.0% Convertible Notes Due 2008
Date:9/6/2007

nformation agent at (212) 269-5550, for banks and brokers, or (888) 644-5854 for others.

Neither the NPS Pharmaceuticals Board of Directors nor any other person makes any recommendation as to whether holders of notes should tender their notes, and no one has been authorized to make such a recommendation. Holders of notes must make their own decisions as to whether to tender their notes, and, if they decide to do so, the principal amount of notes to tender.

This announcement is not an offer to buy or the solicitation of an offer to sell any notes. The tender offer for NPS Pharmaceuticals' 3.0% Convertible Notes due 2008 will be made solely by and subject to the terms and conditions set forth in a Schedule TO (including an offer to purchase, related letter of transmittal and other tender offer documents) that is being filed by NPS Pharmaceuticals today with the Securities and Exchange Commission. The Schedule TO will contain important information and should be read carefully before any decision is made with respect to the tender offer. The offer to purchase, letter of transmittal and other tender offer documents are being delivered to holders of the notes. Once the Schedule TO and other documents are filed with the SEC, they will be available free of charge on the SEC's website at http://www.sec.gov, on NPS Pharmaceuticals' website at http://www.npsp.com or by contacting the NPS Pharmaceuticals Corporate Secretary at (800) 730-3644.

NPS Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of small molecules and recombinant proteins as drugs, primarily for the treatment of metabolic, bone and mineral, and central nervous system disorders. The company has drug candidates in various stages of clinical development. Additional information is available on the company's website, '/>"/>

SOURCE NPS Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Midwest colleges strong contenders for NIH funds
4. Versatile Transfection Reagent Offers Low Toxicity and Consistent Performance
5. Ambion Offers Gene Expression Profiling Service
6. CIO Leadership Series: Snap-Ons Moreno offers lessons in IT transformation
7. In pursuit of capital, be sure to track your private offering
8. Ethics Board site offers welcome contrast to state IT mistakes
9. Visions: Preizler offers insurers perspective on healthcare IT
10. State to offer $850K in high-tech training grants
11. Hewlett-Packard exec offers innovative counsel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... BEACH, Fla. , July 11, 2014 /PRNewswire-iReach/ -- ... of high-quality peptides that are used solely in scientific ... honor two successful years in business, Maxim Peptide, which ... has just launched a new and updated website that ... research blog section has been updated with fascinating articles ...
(Date:7/11/2014)... July 11, 2014 EPFL and ... the appointment of John P. Donoghue . The ... Geneva . The new Wyss ... in Geneva , has named as ... John P. Donoghue , founder of Brown University,s ...
(Date:7/10/2014)... 10, 2014 Women in the ... to an additional family planning option. Sayana® Press ... at all levels of the health system and ... a widely used contraceptive—Pfizer’s Depo-Provera® (depot medroxyprogesterone acetate)—with ... is the first of four African countries expected ...
(Date:7/10/2014)... Boston, Mass. (PRWEB) July 10, 2014 ... , today announced that Alan Swahn, a former vice ... Terascala’s executive team as vice president of marketing. Terascala’s ... from Dell and NetApp create the highest performance and ... has been appointed to guide Terascala’s channel expansion and ...
Breaking Biology Technology:Maxim Peptide Celebrates Second Anniversary Online with an Updated Website and Special Deals Section 2John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 2John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 2Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 5Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 6Terascala Expands Executive Team 2Terascala Expands Executive Team 3
... 2012 The National Foundation for Cancer Research announced ... have been awarded the 7th annual Szent-Gyorgyi Prize for ... led to the successful development of a new therapeutic ... By combining traditional Chinese medicine with Western medicine, Drs. ...
... University of Pennsylvania research team have shown that they can ... Pigmentosa, or XLRP, in dogs. The disease in humans ... and results in early, severe and progressive vision loss. It ... degeneration in man. "Every single abnormal feature that ...
... is largely transparent to the eye and, as it turns ... by scientists at Rice University and Rensselaer Polytechnic Institute (RPI) ... wet when clad by a single continuous layer of graphene ... in the online edition of Nature Materials , is ...
Cached Biology Technology:Chinese Scientists Zhen-Yi Wang and Zhu Chen Awarded 7th Annual Szent-Gyorgyi Prize for Progress in Cancer Research 2Chinese Scientists Zhen-Yi Wang and Zhu Chen Awarded 7th Annual Szent-Gyorgyi Prize for Progress in Cancer Research 3Chinese Scientists Zhen-Yi Wang and Zhu Chen Awarded 7th Annual Szent-Gyorgyi Prize for Progress in Cancer Research 4Chinese Scientists Zhen-Yi Wang and Zhu Chen Awarded 7th Annual Szent-Gyorgyi Prize for Progress in Cancer Research 5Gene therapy research from Penn Vet & Scheie Eye Inst. cures retinitis pigmentosa in dogs 2Gene therapy research from Penn Vet & Scheie Eye Inst. cures retinitis pigmentosa in dogs 3Water sees right through graphene 2
(Date:7/11/2014)... at the Department of Energy,s Oak Ridge National ... by R&D Magazine in recognition of the year,s ... the tremendous value of our National Labs," said ... at the National Labs continues to help our ... scientific and technological innovations necessary to remain globally ...
(Date:7/11/2014)... German . ... refraction of X-rays through a specimen instead of attenuation ... are often of much higher quality than those based ... Franz Pfeiffer are particularly interested in developing new approaches ... phase-contrast imaging. One main goal is to make this ...
(Date:7/11/2014)... other group members to reduce aggression and gain access ... for grooming activities shows a certain pattern across the ... journal Biology Letters . , Grooming between individuals ... ulterior motives. To be groomed has hygienic benefits and ... individual can provide access to infants, mating opportunities and ...
Breaking Biology News(10 mins):ORNL wins eight R&D 100s 2ORNL wins eight R&D 100s 3ORNL wins eight R&D 100s 4New simple setup for X-ray phase contrast 2Baboons groom early in the day to get benefits later 2
... against nature when scientists succeeded in creating a new ... naturally occurring enzyme has evolved. This achievement opens the ... applications in medicine and industry. Enzymes are, ... intricate works of nature. These molecular machines which ...
... Over two hundred million humans depend for their subsistence on ... - and orders its partners, the symbiotic algae, to make ... delicate and complex partnerships a collaboration now facing grave ... a primitive animal and zooxanthellae, tiny one-celled plants, is ...
... RELEASE Toward a new generation of vaccines ... Chemical Research Researchers in Colombia, South America, ... of synthetic vaccines that could lead to more effective ... diseases. These conditions kill more than 17 million people ...
Cached Biology News:Birth of an enzyme 2Birth of an enzyme 3Coral's addiction to 'junk food' 2Coral's addiction to 'junk food' 3American Chemical Society's Weekly PressPac -- March 19, 2008 2American Chemical Society's Weekly PressPac -- March 19, 2008 3American Chemical Society's Weekly PressPac -- March 19, 2008 4American Chemical Society's Weekly PressPac -- March 19, 2008 5American Chemical Society's Weekly PressPac -- March 19, 2008 6American Chemical Society's Weekly PressPac -- March 19, 2008 7American Chemical Society's Weekly PressPac -- March 19, 2008 8American Chemical Society's Weekly PressPac -- March 19, 2008 9